Loading...
XSTO
DMYD B
Market cap16mUSD
Jul 09, Last price  
1.17SEK
1D
2.63%
1Q
-18.18%
Jan 2017
-79.70%
IPO
-54.65%
Name

Diamyd Medical AB

Chart & Performance

D1W1MN
XSTO:DMYD B chart
P/E
—
P/S
1,205.97
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.70%
Rev. gr., 5y
-17.54%
Revenues
130k
0.00%
113,028,000280,752,000514,000100,000443,000513,000757,000922,000726,0001,568,000341,000253,000454,000546,000130,000130,000
Net income
-170m
L+11.81%
-332,000102,570,000-16,242,000-12,633,000-16,034,000-21,397,000-32,008,000-25,555,000-43,953,000-36,731,0009,709,00060,046,000-103,517,000-116,073,000-151,850,000-169,777,000
CFO
-170m
L+31.35%
225,774,000-94,027,000-55,987,000-13,715,000-16,690,000-18,311,000-17,752,000-25,808,000-41,564,000-39,185,00016,880,000-109,468,000-93,219,000-110,962,000-129,181,000-169,683,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company is advancing two key therapeutic candidates. Its flagship product, Diamyd, is an antigen-specific immunotherapy vaccine for diabetes currently undergoing Phase IIb clinical studies for both type 1 diabetes and latent autoimmune diabetes. Additionally, Remygen, an oral drug candidate with regenerative and immunomodulatory properties, is progressing through Phase I/II clinical trials for the treatment of autoimmune and type 2 diabetes.
URL
https://www.diamyd.com/
IPO date
May 20, 2013
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑082024‑082023‑082022‑082021‑082020‑082019‑082018‑082017‑082016‑08
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT